Effect of lipid matrix on repaglinide-loaded solid lipid nanoparticles for oral delivery

2010 ◽  
Vol 1 (1) ◽  
pp. 63-73 ◽  
Author(s):  
Manoj K Rawat ◽  
Achint Jain ◽  
Amit Mishra ◽  
Madaswamy S Muthu ◽  
Sanjay Singh
Keyword(s):  
Solid Lipid Nanoparticles ◽  
Oral Delivery ◽  
Lipid Nanoparticles ◽  
Lipid Matrix ◽  
Solid Lipid

Solid lipid nanoparticles for oral delivery of curcumin

Planta Medica ◽  
2013 ◽  
Vol 79 (13) ◽  
Author(s):  
C Righeschi ◽  
M Bergonzi ◽  
B Isacchi ◽  
A Bilia
Keyword(s):  
Solid Lipid Nanoparticles ◽  
Oral Delivery ◽  
Lipid Nanoparticles ◽  
Solid Lipid

Optimization of Solid Lipid Nanoparticles of Ezetimibe in Combination with Simvastatin Using Quality by Design (QbD)

2020 ◽  
Vol 10 (4) ◽  
pp. 404-418
Author(s):  
Kruti Borderwala ◽  
Ganesh Swain ◽  
Namrata Mange ◽  
Jaimini Gandhi ◽  
Manisha Lalan ◽  
...  
Keyword(s):  
Particle Size ◽  
Solid Lipid Nanoparticles ◽  
High Speed ◽  
Entrapment Efficiency ◽  
Lipid Nanoparticles ◽  
Water Soluble ◽  
Lipid Matrix ◽  
Solid Lipid ◽  
32 Factorial Design ◽  
Full Factorial Experimental Design

Background: The objective of this study was to develop solid lipid nanoparticles (SLNs) of poorly water soluble anti-hyperlipidemic drugs-Ezetimibe in combination with Simvastatin. Methods: This study describes a 32 full factorial experimental design to optimize the formulation of drug loaded lipid nanoparticles (SLN) by the high speed homogenization technique. The independent variables amount of lipid (GMS) and amount of surfactant (Poloxamer 188) were studied at three levels and arranged in a 32 factorial design to study the influence on the response variables- particle size, % entrapment efficiency (%EE) and cumulative drug release (% CDR) at 24 h. Results: The particle size, % EE and % CDR at 24 h for the 9 batches (B1 to B9) showed a wide variation of 104.6-496.6 nm, 47.80-82.05% (Simvastatin); 48.60-84.23% (Ezetimibe) and 54.64-92.27% (Simvastatin); 43.8-97.1% (Ezetimibe), respectively. The responses of the design were analysed using Design Expert 10.0.2. (Stat-Ease, Inc, USA), and the analytical tools of software were used to draw response surface plots. From the statistical analysis of data, polynomial equations were generated. Optimized formulation showed particle size of 169.5 nm, % EE of 75.43% (Simvastatin); 79.10% (Ezetimibe) and 74.13% (Simvastatin); 77.11% (Ezetimibe) %CDR after 24 h. Thermal analysis of prepared solid lipid nanoparticles gave indication of solubilisation of drugs within lipid matrix. Conclusion: Fourier Transformation Infrared Spectroscopy (FTIR) showed the absence of new bands for loaded solid lipid nanoparticles indicating no interaction between drugs and lipid matrix and being only dissolved in it. Electron microscope of transmission techniques indicated sphere form of prepared solid lipid nanoparticles with smooth surface with size approximately around 100 nm.

Preparation, Characterization and Optimization of Irbesartan Loaded Solid Lipid Nanoparticles for Oral Delivery

2021 ◽  
pp. 97-104
Author(s):  
Kumara Swamy S ◽  
Ramesh Alli
Keyword(s):  
Drug Release ◽  
Solid Lipid Nanoparticles ◽  
Oral Bioavailability ◽  
Oral Delivery ◽  
Entrapment Efficiency ◽  
Lipid Nanoparticles ◽  
Sustained Drug Release ◽  
Bioavailability Enhancement ◽  
Solid Lipid

The purpose of this study was to develop and evaluate irbesartan (IS) loaded solid lipid nanoparticles (SLNs; IS-SLNs) that might enhance the oral bioavailability of IS. IS, an angiotensin-receptor antagonist, used to treat hypertension. However, poor aqueous solubility and poor oral bioavailability has limited therapeutic applications of IS. Components of the SLNs include either of trimyristin/tripalmitin/tristearin/trilaurate/stearic acid/beeswax, and surfactants (Poloxamer 188 and soylecithin). The IS-SLNs were prepared by hot homogenization followed by ultrasonication method and evaluated for particle size, poly dispersity index (PDI), zeta potential (ZP), entrapment efficiency (EE), drug content and in vitro drug release. The physical stability of optimized formulation was studied at refrigerated and room temperature for two months. The optimized IS-SLN formulation (F4) had a mean diameter of about 217.6±3.62 nm, PDI of 0.163±0.032, ZP of -28.5±4.12, assay of 99.8±0.51 and EE of 93.68±2.47%. The formulation showed sustained drug release compared with control formulation over 24 h. Optimized formulation was found to be stable over two months. IS-SLN showed nearly spherical in shape using and converted to amorphous form by DSC. Thus, the results conclusively demonstrated SLNs could be considered as an alternative delivery system for the oral bioavailability enhancement of IS.

Fermentation of bioactive solid lipid nanoparticles by human gut microflora

2016 ◽  
Vol 7 (1) ◽  
pp. 516-529 ◽  
Author(s):  
Ana Raquel Madureira ◽  
Débora Campos ◽  
Beatriz Gullon ◽  
Cláudia Marques ◽  
Luís M. Rodríguez-Alcalá ◽  
...  
Keyword(s):  
Phenolic Compounds ◽  
Intestinal Epithelium ◽  
Solid Lipid Nanoparticles ◽  
Oral Delivery ◽  
Lipid Nanoparticles ◽  
Gut Microflora ◽  
Human Gut ◽  
Solid Lipid ◽  
Harsh Conditions

Solid lipid nanoparticles (SLNs) can be used for oral delivery of phenolic compounds in order to protect them from the harsh conditions of digestion and improve their bioavailability in the intestinal epithelium.

scholarly journals Preparation and Optimization of Triptolide-Loaded Solid Lipid Nanoparticles for Oral Delivery with Reduced Gastric Irritation

Molecules ◽  
2013 ◽  
Vol 18 (11) ◽  
pp. 13340-13356 ◽  
Author(s):  
Cong Zhang ◽  
Conghui Gu ◽  
Fan Peng ◽  
Wei Liu ◽  
Jiangling Wan ◽  
...  
Keyword(s):  
Solid Lipid Nanoparticles ◽  
Oral Delivery ◽  
Lipid Nanoparticles ◽  
Solid Lipid ◽  
Gastric Irritation
Sign in / Sign up

Export Citation Format

Share Document